Abeona Therapeutics (ABEO) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Abeona Therapeutics (ABEO) over the past year, losing 11.9% versus a loss of 46.0%. Over five years, IFRX leads with a -79.5% price change compared with -86.7% for ABEO. Abeona Therapeutics is the larger company by market cap ($165.3 million vs $153.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | IFRX |
|---|---|---|
| Share price | $2.42 | $1.04 |
| Market cap | $165.31M | $153.26M |
| 1-day change | -1.22% | -4.59% |
| YTD return | -54.08% | +2.97% |
| 1-year return | -45.98% | -11.86% |
| 5-year return | -86.74% | -79.53% |
| EPS (TTM) | $-1.16 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | — |
| Net income (latest FY) | $71.18M | — |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | — |
| Net margin | 1223.08% | — |
| 52-week high | $7.65 | $2.95 |
| 52-week low | $2.09 | $0.798 |
| Distance from 52-week high | -68.37% | -64.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +542.98% | +696.15% |
| Average volume | 1.66M | 868.66K |
| Shares outstanding | 68.31M | 147.37M |
| Employees | 226 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed ABEO by 34.1 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ABEO vs IFRX FAQ
Which is bigger, Abeona Therapeutics or InflaRx N.V.?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $165.31M compared with $153.26M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, ABEO or IFRX?
IFRX returned -11.86% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.